Omeros (OMER) Stock Rallies 149% on $2 Billion Novo Nordisk Deal

TLDR Omeros Corporation stock jumped 149% to $10.19 after signing a $2.1 billion licensing deal with Novo Nordisk for its MASP-3 inhibitor drug zaltenibart. Novo Nordisk will pay $340 million upfront and near-term payments, with potential milestone payments reaching $2.1 billion total. Trading volume exploded to 77.9 million shares compared to the typical 1.2 million [...]

The post Omeros (OMER) Stock Rallies 149% on $2 Billion Novo Nordisk Deal appeared first on Blockonomi.